is retatrutide a glp-1 Retatrutide, an experimental weight-loss drug,

The stories circulate

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus

Simultaneously, it slows gastric emptying, increases pancreatic -cell proliferation, and reduces glucagon release, contributing to an overall reduction in appetite thus also promoting weight loss [1-3]

Risk of depression with GLP-1 receptor agonists use in overweight or obese adults with type 2 diabetes: a new-user, active-comparator cohort study

October 2, 2025: Eli Lilly has expanded Mounjaros indication to include children aged 10 to 17 with type 2 diabetes